Eupraxia Pharmaceuticals (EPRX) Shares Outstanding (2022 - 2026)

Eupraxia Pharmaceuticals (EPRX) has reported Shares Outstanding (Entity) for 5 consecutive years, with $56.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Shares Outstanding (Entity) rose 58.92% year-over-year to $56.7 million; the TTM figure through Mar 2026 stood at $56.7 million (up 58.92% YoY), while the FY2025 annual figure was $40.0 million, up 12.11% from the prior year.
• Shares Outstanding (Entity) climbed to $56.7 million in Q1 2026 per EPRX's latest filing, from $40.0 million in the prior quarter.
• Across five years, Shares Outstanding (Entity) topped out at $56.7 million in Q1 2026 and bottomed at $21.6 million in Q4 2022.
• Historically, Shares Outstanding (Entity) has averaged $32.8 million across 5 years, with a median of $35.6 million in 2024.
• Annual changes were most pronounced in 2024 — Shares Outstanding (Entity) surged 61.85% — and 2025, when it climbed 0.81%.
• Eupraxia Pharmaceuticals' Shares Outstanding (Entity) stood at $21.6 million in 2022, then climbed by 26.35% to $27.3 million in 2023, then soared by 30.64% to $35.6 million in 2024, then climbed by 12.11% to $40.0 million in 2025, then surged by 41.94% to $56.7 million in 2026.
• Business Quant data shows EPRX's Shares Outstanding (Entity) at $56.7 million in Q1 2026, $40.0 million in Q4 2025, and $36.9 million in Q3 2025.